Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 15/20 | 0.82 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.75 |
| ▸ | CNR2 | P34972 | 2/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.73 |
| ▸ | APLNR | P35414 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28729777 | 0.94 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL1615022 | 0.90 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1279440 | 0.89 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL12260294 | 0.88 | TAS2R14 (0.72) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL31455590 | 0.87 | TAS2R14 (0.64) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL14285692 | 0.87 | TAS2R14 (0.64) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL1278846 | 0.86 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1279080 | 0.86 | TAS2R14 (0.77) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL1169926 | 0.86 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1279036 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | claimed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-13 | — | — | US | disclosed |
| CN-117460720-A | Preparation method of heterocycloalkyl compound, intermediate and application thereof | 武汉朗来科技发展有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115996924-A | Substituted pyrazolyl compounds and methods of use thereof | 奇努克医疗加拿大公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-111377917-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115380036-A | SSTR5 antagonists | 卡尔优普公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4073075-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | TAS2R14 4697/4885CXCR3 2134/4885PTGES 1219/4885 |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | TAS2R14 4832/4885CXCR3 4615/4885PTGES 3702/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAS2R14 1478/4885CXCR3 212/4885PTGES 2612/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAS2R14 1408/4885CXCR3 194/4885PTGES 2813/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAS2R14 1408/4885CXCR3 194/4885PTGES 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.